Risk factor
Poor trading liquidity
Profitability factor
Greatly undervalued vs peers
About
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine,...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITDA, under
Target Price
The average target price of GBT.PA is 14 and suggests 6% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
Buy
Sell